Recruiting

Methamphetamine Use

Sponsor:

William Stoops

Code:

NCT07226596

Conditions

Methamphetamine Use Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Contingency Management

Study Details

Brief summary:

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

Conditions

Methamphetamine Use Disorder

Study ID

NCT07226596

Start date

Jan 14, 2026

Status verified date

Jun, 2026

Completion date

Jan 4, 2031

Anticipated

Primary completion date

Jan 4, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • be age 18 years or older;
  • self-report methamphetamine use in the week prior to screening;
  • provide a methamphetamine-positive urine sample at screening;
  • meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);
  • be seeking treatment for their methamphetamine use
  • be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up
  • Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion Criteria:

  • current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians
  • poor venous access precluding blood draws

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

no intervention: Control Group

This group will receive payment for providing urine samples throughout the trial.

experimental: Contingency Management Group

This group will receive payment for providing methamphetamine negative urine samples throughout the trial.

Interventions

Contingency Management

Subjects will receive payments for providing methamphetamine negative urine samples.

Primary outcome measure

  • Mean Arterial Pressure [ Time Frame: At baseline. ]
  • Mean Arterial Pressure [ Time Frame: Week 1 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 2 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 3 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 4 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 5 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 6 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 7 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 8 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 8 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 9 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 10 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 11 of participation. ]
  • Mean Arterial Pressure [ Time Frame: Week 12 of participation. ]
  • Endothelin-1 [ Time Frame: At baseline. ]
  • Endothelin-1 [ Time Frame: Week 6 of participation. ]
  • Endothelin-1 [ Time Frame: Week 12 of participation. ]

Central Contacts and Locations

Central contacts

William W Stoops, PhD

8592575388william.stoops@uky.edu

Locations

Psychopharmacology of Addiction Laboratory

Recruiting

Lexington, Kentucky, United States, 40507

Contacts

William W Stoops, PhD

859-257-5388william.stoops@uky.edu

More Information

Sponsor

William Stoops

Last update posted

Jun 8, 2026

Last verified

Jun, 2026

Keywords

  • methamphetamine
  • treatment
  • behavioral intervention

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by William Stoops on 2026-06-08.